Symproic tablets 0.2 mg for opioid-induced constipation (naldemedine tosilate)

Are Symproic tablets 0.2 mg effective for opioid-induced constipation (naldemedine tosilate)?

Opioid medications are highly effective in managing chronic pain, but one of their most common and frustrating side effects is constipation. For those dealing with this challenge, Symproic tablets containing naldemedine tosilate offer a clinically proven solution specifically designed for opioid-induced constipation treatment.

Symproic is not just another laxative. It contains naldemedine tosilate, a peripherally acting μ-opioid receptor antagonist (PAMORA), developed to target the underlying cause of constipation without affecting the pain-relieving effects of opioids. By acting on opioid receptors in the gastrointestinal tract, Symproic restores natural bowel function without compromising pain control.

Why Choose Symproic Tablets?

Patients and healthcare providers trust Symproic due to its well-documented efficacy and safety profile. Clinical studies, including the study titled “Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects” (S. Ohnishi et al., Xenobiotica, 2019), confirmed that naldemedine was rapidly absorbed and well tolerated, with no major safety concerns.

Key Benefits of Symproic Tablets for Constipation Caused by Opioids

• Targets the cause: Unlike conventional laxatives, Symproic works directly by blocking opioid action in the gut.
• Proven results: Clinical trials in Japan and abroad support its consistent effectiveness in managing opioid-induced constipation.
• No compromise on pain relief: Maintains the central analgesic effects of opioids while relieving constipation.
• Well tolerated: Most patients experience minimal side effects and improved quality of life.
• Convenient oral tablet form: Easy to integrate into daily medication regimens.

Symproic is a valuable option for patients who have not found relief from traditional over-the-counter laxatives or dietary adjustments. Its effectiveness as a tablet for constipation caused by opioids makes it a preferred choice among healthcare professionals managing long-term opioid therapy.

Naldemedine Tosilate Tablets: Backed by Science

Developed by Japanese pharmaceutical leader Shionogi, naldemedine tosilate tablets represent years of research and development in addressing one of the most persistent side effects of opioid use. The active ingredient, a derivative of naltrexone, is carefully designed to act peripherally without crossing the blood-brain barrier, reducing risks of opioid withdrawal or loss of pain control.

For those experiencing the discomfort and disruption of opioid-related constipation, naldemedine tosilate tablets like Symproic offer a targeted and effective solution. As a trusted opioid-induced constipation treatment, Symproic provides fast relief and lasting comfort—improving overall well-being while keeping pain management on track.

Package details: 14 tablets

Dosage and administration: adults should take 1 tablet (0.2 mg of naldemedine) at a time, once daily.

Active components: naldemedine tosilate

Therapeutic effect: treatment of opioid-induced constipation.

Contraindications and precautions: Store in a dry cool place, out of reach of children. Do not use for pregnant or breastfeeding women. Strictly avoid breastfeeding while taking this medicine. Do not use for patients with gastrointestinal obstruction or suspicion of it or patients with a history of gastrointestinal obstruction and risk of its reoccurrence. Do not expose to sunlight or heat. In case of severe diarrhea consult your doctor. If allergic symptoms occur, discontinue use.